Telomir Pharmaceuticals Announces Board and Officer Changes
Ticker: TELO · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1971532
Sentiment: neutral
Topics: leadership-change, board-of-directors, officer-appointment
TL;DR
Telomir Pharma shakes up its board and exec team, new hires and pay details filed.
AI Summary
Telomir Pharmaceuticals, Inc. announced on November 18, 2024, changes in its board of directors and officer appointments. Specifically, the company elected new directors and appointed certain officers, alongside updates to compensatory arrangements for these officers. The filing details the departure and election of directors and the appointment of key personnel.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or governance, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensatory arrangements can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- November 18, 2024 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of new directors and the departure of certain officers, but does not list the specific names of individuals departing or being elected in this section.
Were there any changes in executive officer positions?
Yes, the filing notes the appointment of certain officers.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is November 18, 2024.
In which state is Telomir Pharmaceuticals, Inc. incorporated?
Telomir Pharmaceuticals, Inc. is incorporated in Florida.
What is the principal executive office address of Telomir Pharmaceuticals, Inc.?
The principal executive office is located at 100 SE 2nd St., Ste 2000 #1009, Miami, Florida, 33131.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-11-21 16:15:23
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TELO The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-047145.txt ( ) — 211KB
- telo-20241118.xsd (EX-101.SCH) — 3KB
- telo-20241118_lab.xml (EX-101.LAB) — 33KB
- telo-20241118_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Date: November 21, 2024 By: /s/ Erez Aminov Erez Aminov Chief Financial Officer